Literature DB >> 17646897

Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis.

Bruno Seriolo, Sabrina Paolino, Carmela Ferrone, Maurizio Cutolo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17646897     DOI： 10.1007/s10067-007-0702-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  6 in total

1.  Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

Authors:  A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

2.  Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis.

Authors:  Lai-Shan Tam; Brian Tomlinson; Tanya T Chu; Tena K Li; Edmund K Li
Journal:  Clin Rheumatol       Date:  2007-01-20       Impact factor: 2.980

3.  Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.

Authors:  Marijn Vis; Michael T Nurmohamed; Gertjan Wolbink; Alexandre E Voskuyl; Margret de Koning; Rob van de Stadt; Jos W R Twisk; Ben A C Dijkmans; Willem F Lems
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

4.  Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.

Authors:  M A Gonzalez-Gay; J M De Matias; C Gonzalez-Juanatey; C Garcia-Porrua; A Sanchez-Andrade; J Martin; J Llorca
Journal:  Clin Exp Rheumatol       Date:  2006 Jan-Feb       Impact factor: 4.473

5.  Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  D N Kiortsis; A K Mavridis; S Vasakos; S N Nikas; A A Drosos
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

6.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

Authors:  E Bonora; S Kiechl; J Willeit; F Oberhollenzer; G Egger; G Targher; M Alberiche; R C Bonadonna; M Muggeo
Journal:  Diabetes       Date:  1998-10       Impact factor: 9.461
  6 in total
  8 in total

1.  Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Authors:  Jeffrey R Curtis; Ani John; Onur Baser
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

Review 2.  A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis.

Authors:  Eduardo Nicolas Pollono; Maria A Lopez-Olivo; Juan Antonio Martinez Lopez; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

3.  Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?

Authors:  Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Rheumatol       Date:  2009-06-11       Impact factor: 2.980

4.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 5.  Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals.

Authors:  Calin D Popa; Elke Arts; Jaap Fransen; Piet L C M van Riel
Journal:  Mediators Inflamm       Date:  2012-09-06       Impact factor: 4.711

6.  Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis.

Authors:  Antonios Stavropoulos-Kalinoglou; Giorgos S Metsios; Vasileios F Panoulas; Peter Nightingale; Yiannis Koutedakis; George D Kitas
Journal:  Arthritis Res Ther       Date:  2012-07-05       Impact factor: 5.156

Review 7.  Psoriasis comorbidities: complications and benefits of immunobiological treatment.

Authors:  André Vicente Esteves de Carvalho; Ricardo Romiti; Cacilda da Silva Souza; Renato Soriani Paschoal; Laura de Mattos Milman; Luana Pizarro Meneghello
Journal:  An Bras Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.896

8.  Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy.

Authors:  Norma Alejandra Rodriguez-Jimenez; Carlos E Garcia-Gonzalez; Karina Patricia Ayala-Lopez; Benjamin Trujillo-Hernandez; Erika Anita Aguilar-Chavez; Alberto Daniel Rocha-Muñoz; Jose Clemente Vasquez-Jimenez; Eva Olivas-Flores; Mario Salazar-Paramo; Esther Guadalupe Corona-Sanchez; Monica Vazquez-Del Mercado; Evangelina Varon-Villalpando; Adolfo Cota-Sanchez; Ernesto German Cardona-Muñoz; Jorge I Gamez-Nava; Laura Gonzalez-Lopez
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.